Gilead poaches Genentech exec
Merdad Parsey is set to join Gilead as chief medical officer in November. He will be responsible for the company’s global clinical development and medical affairs. Parsey was previously SVP of early clinical development for Genentech’s research and early development group.
Zosano Pharma names CEO
Zosano Pharma has named Steven Lo as president and chief executive officer, replacing retiring CEO John Walker, who will stay on as board chairman. Previously, Lo was chief commercial officer at Puma Biotechnology.
Ashfield hires U.K. business development director
Ashfield has appointed Richard Clarke as commercial and patient solutions business development director in the U.K. He previously served in national and global roles at GlaxoSmithKline and AstraZeneca. Clarke is also part of Ashfield’s U.K. management team.
Avid Bioservices names former Rubicon exec as COO
Richard Richieri was named COO at Avid Bioservices. Most recently, he was founding partner and COO at Rubicon Biotechnology. Earlier in his career, Richieri spent nearly 15 years at Avid Bioservices.
Hepion Pharmaceuticals promotes three
Hepion Pharmaceuticals has promoted Daren Ure to chief scientific officer. The company also named Daniel Trapanier as SVP of drug development and Patrick Mayo as SVP of clinical pharmacology.
Deciphera Pharmaceuticals appoints chief medical officer
Matthew Sherman has joined Deciphera Pharmaceuticals as EVP and chief medical officer. Previously, he served as chief medical officer at Acceleron Pharma for more than a decade.
Client-side people moves courtesy of MM&M sister brand The PMD. The Escalator is a weekly roundup of notable people moves in the pharmaceutical and healthcare marketing industries. For submissions, email Carrie Gavit at firstname.lastname@example.org.